Results from a phase IIa randomized, double-blind, placebo-controlled, exploratory, multicentre study of GBR 830 in adults with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Guttman-Yassky, E. [1 ]
Pavel, A. [1 ]
Estrada, Y. [1 ]
Zhang, N. [1 ]
Peng, X. [1 ]
Xu, H. [1 ]
Wen, H. [1 ]
Fang, H. [2 ]
Salhi, Y. [2 ]
Gudi, G. [3 ]
Ca, V. [3 ]
Gn, S. [3 ]
Grossman, F. [2 ]
Wolff, G. [2 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Glenmark Pharmaceut Inc, Paramus, NJ USA
[3] Glenmark Pharmaceut Ltd, Navi Mumbai, Maharashtra, India
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2018年 / 179卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P072
引用
收藏
页码：E44 / E45
页数：2
相关论文
共 50 条
  • [1] Results from a randomized, double-blind, placebo-controlled, exploratory, multicenter study of GBR 830 in adult patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, Emma
    Pavel, Ana B.
    Estrada, Yeriel
    Zhang, Ning
    Peng, Xiangyu
    Xu, Hui
    Wen, Huei-Chi
    Fang, Hui
    Salhi, Yacine
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB245 - AB245
  • [2] Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study
    Bissonnette, Robert
    Abramovits, William
    Proulx, Etienne Saint-Cyr
    Lee, Patricia
    Guttman-Yassky, Emma
    Zovko, Elizabeta
    Sigmund, Ralf
    Willcox, Joanne
    Bieber, Thomas
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (03) : 549 - 557
  • [3] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Tyring, Stephen K. K.
    Rich, Phoebe
    Tada, Yayoi
    Beeck, Stefan
    Messina, Izabella
    Liu, Jie
    Huang, Xiaohong
    Shumack, Stephen
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
  • [4] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Stephen K. Tyring
    Phoebe Rich
    Yayoi Tada
    Stefan Beeck
    Izabella Messina
    Jie Liu
    Xiaohong Huang
    Stephen Shumack
    [J]. Dermatology and Therapy, 2023, 13 : 595 - 608
  • [5] Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study
    Bieber, Thomas R. M.
    Thaci, Diamant
    Graham, Neil
    Pirozzi, Gianluca
    Teper, Ariel
    Ren, Haobo
    Radin, Allen
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB404 - AB404
  • [6] Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
    Danese, Silvio
    Rudzinski, Janusz
    Brandt, Wolfgang
    Dupas, Jean-Louis
    Peyrin-Biroulet, Laurent
    Bouhnik, Yoram
    Kleczkowski, Dariusz
    Uebel, Peter
    Lukas, Milan
    Knutsson, Mikael
    Erlandsson, Fredrik
    Hansen, Mark Berner
    Keshav, Satish
    [J]. GUT, 2015, 64 (02) : 243 - 249
  • [7] Montelukast treatment of moderate to severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled trial
    Veien, NK
    Busch-Sorensen, M
    Stausbol-Gron, B
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (01) : 147 - 149
  • [8] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
    Zhao, Y.
    Wu, L.
    Lu, Q.
    Gao, X.
    Zhu, X.
    Yao, X.
    Li, L.
    Li, W.
    Ding, Y.
    Song, Z.
    Liu, L.
    Dang, N.
    Zhang, C.
    Liu, X.
    Gu, J.
    Wang, J.
    Geng, S.
    Liu, Q.
    Guo, Y.
    Dong, L.
    Su, H.
    Bai, L.
    O'Malley, J. T.
    Luo, J.
    Laws, E.
    Mannent, L.
    Ruddy, M.
    Amin, N.
    Bansal, A.
    Ota, T.
    Wang, M.
    Zhang, J.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
  • [9] Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial
    Silverberg, J. I.
    Toth, D.
    Bieber, T.
    Alexis, A. F.
    Elewski, B. E.
    Pink, A. E.
    Hijnen, D.
    Jensen, T. N.
    Bang, B.
    Olsen, C. K.
    Kurbasic, A.
    Weidinger, S.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 450 - 463
  • [10] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
    Torrelo, A.
    Rewerska, B.
    Paller, Amy
    Prakash, A.
    Zhu, D.
    Pontes, M.
    Wu, Wen-Shuo
    Eichenfield, Lawrence F.
    Boecker, Ulrike
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
12345